ip6k1

LI-2242 is a potent inositol hexakisphosphate kinase (IP6K) inhibitor with IC50s of 31 nM, 42 nM, 8.7 nM, and 1944 nM for IP6K1, IP6K2, IP6K3, and IPMK, respectively.LI-2242 ameliorated hepatic steatosis by reducing the expression of genes that enhance lipid uptake, lipid stabilization, and adipogenesis, and enhanced mitochondrial oxygen consumption rate (OCR) and insulin signaling in adipocytes and hepatocytes in vitro. LI-2242 ameliorated diet-induced obesity, hyperglycemia and hepatic steatosis in mice.LI-2242 can be used to study type II diabetes, obesity, metabolic complications, venous thrombosis and psychiatric disorders.

TNP (IP3K Inhibitor) is a cell-permeable inhibitor of IP6K1 and IP3K, with IC 50 values of 0.55 μM and 10.2 μM for IP6K1 and IP3K, respectively. TNP binds to the ATP-binding sites of both enzymes [1].

UNC7467 is a potent IP6K inhibitor with IC50 values of 4.9 nM for IP6K2, 8.9 nM for IP6K1, and 1320 nM for IP6K6. It effectively reduces inositol pyrophosphate levels without significantly affecting other inositol phosphates and is applicable for obesity research [1].

IP6K2-IN-2 (Compound 6) is an inhibitor of IP6K2, with IC50 values of 0.58 μM, 0.86 μM, and 3.08 μM for IP6K2, IP6K1, and IP6K3, respectively. It is applicable in obesity research.

TBK1 IKKε-IN-3, a potent IP6K inhibitor, exhibits IC50 values of 3, 8.65, and 3.72 μM for IP6K1, IP6K2, and IP6K3, respectively. It is applicable in obesity disease research. [1]